ArticleEuropean journal of nuclear medicine and molecular imaging2026
Beyond nigrostriatal dopamine transporter loss: whole-brain DAT depletion patterns discriminate PD phenotypes.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeTo map whole-brain dopamine transporter (DAT) depletion patterns in Parkinson’s disease (PD) using 11C-CFT PET and evaluate their utility in distinguishing tremor-dominant (TD) and postural instability/gait difficulty (PIGD) subtypes in early PD.
methodsThis retrospective study included 197 PD patients (80 TD, 117 PIGD) and 21 healthy controls. 11C-CFT PET quantified DAT availability across nigrostriatal and extrastriatal regions. Differential DAT availability was assessed using FDR-corrected t-tests and Cohen’s d. LASSO-optimized features from nigrostriatal (NS), extranigral (ONS), and whole-brain (WB) regions informed three classification models (Support vector machine, Logistic Regression, Random Forest), evaluated via Receiver Operating Characteristic analysis.
results197 patients (mean age 50 ± 10 years; 112 men) were evaluated. Beyond classical nigrostriatal reductions, PD patients exhibited significant DAT loss in mesolimbic (nucleus accumbens, amygdala), mesocortical (insula), and brainstem-cerebellar regions. PIGD patients demonstrated greater contralateral striatal (putamen: d = 0.58, caudate: d = 0.50; p < 0.05) and limbic (nucleus accumbens: d = 0.51; p = 0.01) DAT depletion compared to TD. The WB model incorporating striatal and extranigral features (posterior putamen, olfactory cortex, parietal regions) achieved superior subtype discrimination (AUC = 0.90) versus NS (AUC = 0.80) and ONS (AUC = 0.82) models. DAT availability in nucleus accumbens correlated with gait freezing (ρ=-0.28; p < 0.001) and autonomic scores (ρ=-0.34; p < 0.001).
conclusion11C-CFT PET reveals distinct whole-brain DAT depletion patterns in PD subtypes, extending beyond nigrostriatal degeneration. The WB model’s superior diagnostic accuracy underscores the critical role of extranigral dopaminergic circuits as biomarkers for early phenotypic stratification. These findings redefine PD as a multisystem dopaminergic disorder and provide a neuroimaging basis for precision phenotyping and therapeutic targeting.
Indexed as
Identifiers
41656420What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.